Results 181 to 190 of about 1,518,423 (359)

The Determinants of Management Expenses [PDF]

This paper develops a model which explains the determinants of the management expenses charged by U.S. equity funds. The study shows that for high quality managers, an increase in quality is associated with higher fees. In contrast, as the quality of the
Michael K. Berkowitz, Yehuda Kotowitz
core  

The Cost of the National Disability Insurance Scheme: Australia's Print‐Media Discourse

Australian Journal of Social Issues, EarlyView.
ABSTRACT This paper examines the way that Australian newspapers have framed the cost of the National Disability Insurance Scheme (NDIS). Introduced in 2013, the NDIS represented a major change in Australia's disability support policy, moving for the first time to a nationwide universal insurance model.
Meera Chinnappa, Jennifer Smith‐Merry, Kuo‐yi Jade Chang   +2 more
wiley   +1 more source

Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study. [PDF]

Res Pract Thromb Haemost
Olasupo OO, Iserman E, Keepanasseril A, Ibrahim Q, Ali Al-Housni ZS, Germini F, Tarride JE, Mbuagbaw L, Jackson S, Blydt-Hansen I, Bech M, Woo C, Belletrutti M, Iorio A, Matino D, Association of Hemophilia Clinic Directors of Canada (AHCDC).   +15 more
europepmc   +1 more source

Specialist fees [PDF]

British Dental Journal, 2010
openaire   +2 more sources

The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen, Vibeke Backer, Anne Sophie Homøe, Thomas H. L. Jensen, Kasper Aanæs, Howraman Meteran, Morten Hostrup, Lukas Moesgaard, Christiane Haase, Peter G. Gibson   +9 more
wiley   +1 more source

Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied.
Steven Chun‐Kang Liao, Aditi Agarwal, Junqin Bai, Zhidi Luo, Siyuan Dong, Regan L. Harmon, Brooke N. Gleason, Julia Huang, David B. Conley, Kevin C. Welch, Stephanie Shintani‐Smith, Robert C. Kern, Atsushi Kato, Lutfiyya N. Muhammad, Bruce K. Tan   +14 more
wiley   +1 more source

CaSMO Recommendations for Prevention and Treatment of Cutaneous Adverse Events Related to Cancer Therapies in Darker Skin Phototypes. [PDF]

Clin Cosmet Investig Dermatol
Fournier C, Sauder MB, Claveau J, Butler MO, Hijal T, Dayeh NR, Lynde CW.   +6 more
europepmc   +1 more source

The Impact of ESG Incidents on Audit Fees: Evidence from China

Yachao Li, Chang Shi, Tao Yuan, Jiawei Zhang   +3 more
openalex   +1 more source

Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022

American Journal of Hematology, EarlyView.
Rong Wang, Amy J. Davidoff, Martin Schoen, John H. Huber, Eric J. Feuer, Jennifer Ruhl, Natalia Neparidze, Xiaomei Ma, Su‐Hsin Chang, Shi‐Yi Wang   +9 more
wiley   +1 more source

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol, Joseph K. Han, Tanya M. Laidlaw, Claire Hopkins, Anju T. Peters, Oliver Pfaar, Martin Desrosiers, Stella E. Lee, Andrew P. Lane, Claudia Chen, Yun Chon, Sandhia S. Ponnarambil, Andrew Foster, Andrew W. Lindsley, Christopher S. Ambrose   +14 more
wiley   +1 more source